Phase 3 N=145 Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
Head and Neck Cancer
Primary: Overall Survival — 73; 78 percent of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=505 Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
Bipolar Depression
Primary: Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6) — -10.7; -15.4; -15.4 units on a scale — p=<0.001
Phase 2 N=11 Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD
Age-Related Macular Degeneration
Primary: Rate of Change in Area of Geographic Atrophy (GA) in the Study Eye at 24 Months as Compared to Baseline — 0.102 MPS DA/month
N/A N=62 A Comparison Chocolate With and Without High Cocoa Solids in Patients With Type 2 Diabetes in a Randomised Clinical Trial
Diabetes Type 2
Primary: Difference in Insulin Resistance (HOMA) Between Treatments After 12 Weeks of Product Intake — 2.82; 2.21; 2.75 HOMA index
N/A N=118 Endometrial Injury and Single Embryo Transfer
Primary Infertility
Primary: Clinical Pregnancy Rate
Phase 2 N=60 Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
Phase 1 N=21 Vitamin D Supplementation in Crohn's Patients
Inflammatory Bowel Disease
Primary: Crohn's Disease Activity Index — 230; 112 units on a scale
Phase 2 N=44 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer
Prostate Cancer
Primary: Number of Patients With Stable Disease at 4 Months. — 2; 5 participants
N/A N=45 Nasal Allergen Challenge in Rhinitic Subjects
Asthma · Allergic Rhinitis
Primary: Change in Sputum Eosinophils Following Allergen Challenge — 5.6; 2.0; 6.0; 1.3 percentage of sputum eosinophils
Phase 2 N=401 Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea
Papulopustular Rosacea
Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Treatment (LOCF: Last Observation Carried Forward) — 43.4…
Phase 2 N=172 A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)
Multiple Sclerosis
Primary: Double Blind Period: Percentage of Participants With Grade 3 or 4 (Common Terminology Criteria for Adverse Events [CTCAE] v 4.0) Hematological or Liver Toxicity — 63.71…
Phase 3 N=264 Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Rheumatoid Arthritis
Primary: American College of Rheumatology (ACR) 20 Response, Using CRP (C-reactive Protein), at Week 14 — 21; 54 Number of participants — p=<0.001
Phase 4 N=7 Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients
Multidrug-resistant Tuberculosis · Extensively Drug-resistant Tuberculosis
Primary: Area Under the Time Concentration Curve (AUC0-12h) of Linezolid in Plasma After Addition of 0mg, 250mg, or 500mg Clarithromycin (CLA). — 36.3; 61.0; 67.2 mg*h/L
N/A N=84 Lifestyle Physical Activity to Reduce Pain and Fatigue in Adults With Fibromyalgia
Fibromyalgia
Primary: Ambulatory Pain (Higher Values Indicate Greater Pain) — 54.6; 58.9; 46.3; 62.4 units on a scale
Phase 3 N=114 PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C
Chronic Hepatitis C
Primary: Sustained Viral Response (SVR) — 29; 12 participants